Pacira BioSciences, Inc. (PCRX)
NASDAQ: PCRX · Real-Time Price · USD
36.46
0.00 (0.00%)
At close: Nov 13, 2026, 4:00 PM EST
36.46
-0.01 (-0.01%)
After-hours: Nov 13, 2026, 7:30 PM EST
Pacira BioSciences Revenue
Pacira BioSciences had revenue of $176.65M in the quarter ending September 30, 2026, a decrease of -1.59%. This brings the company's total for the last twelve months to $743.30M, up 3.70% year-over-year. In the year 2025, Pacira BioSciences had annual revenue of $726.41M with 3.63% growth. That makes Pacira BioSciences the 9,110th largest company in the world by revenue and 2,021st in the United States.
Revenue (ttm)
$743.30M
Revenue Growth
+3.70%
P/S Ratio
1.97
Revenue / Employee
$896,624
Employees
829
Market Cap
1.46B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 726.41M | 25.45M | 3.63% |
| Dec 31, 2024 | 700.97M | 25.99M | 3.85% |
| Dec 31, 2023 | 674.98M | 8.16M | 1.22% |
| Dec 31, 2022 | 666.82M | 125.29M | 23.14% |
| Dec 31, 2021 | 541.53M | 111.89M | 26.04% |
| Dec 31, 2020 | 429.65M | 8.62M | 2.05% |
| Dec 31, 2019 | 421.03M | 83.75M | 24.83% |
| Dec 31, 2018 | 337.28M | 50.65M | 17.67% |
| Dec 31, 2017 | 286.63M | 10.26M | 3.71% |
| Dec 31, 2016 | 276.37M | 27.37M | 10.99% |
| Dec 31, 2015 | 249.00M | 51.33M | 25.97% |
| Dec 31, 2014 | 197.67M | 112.12M | 131.05% |
| Dec 31, 2013 | 85.55M | 46.47M | 118.89% |
| Dec 31, 2012 | 39.08M | 23.40M | 149.12% |
| Dec 31, 2011 | 15.69M | 1.13M | 7.74% |
| Dec 31, 2010 | 14.56M | -444.00K | -2.96% |
| Dec 31, 2009 | 15.01M | 1.08M | 7.76% |
| Dec 31, 2008 | 13.93M | 5.58M | 66.95% |
| Dec 31, 2007 | 8.34M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Perrigo Company | 4.09B |
| Phibro Animal Health | 1.54B |
| Prestige Consumer Healthcare | 1.17B |
| Trulieve Cannabis | 1.08B |
| ANI Pharmaceuticals | 1.04B |
| BioCryst Pharmaceuticals | 961.51M |
| Amphastar Pharmaceuticals | 745.79M |
| Alvotech | 492.31M |
PCRX News
- 2 days ago - Ingram Micro to replace Pacira in S&P 600 at open on 11/17 - TheFly
- 8 days ago - Pacira BioSciences Quarterly report: Q3 2026 - Filings
- 8 days ago - Viatris Reports Third-Quarter 2026 Financial Results - PRNewsWire
- 14 days ago - Viatris commences tender offer to acquire Pacira for $36.50 per share in cash - TheFly
- 14 days ago - Viatris Announces Commencement of Tender Offer to Acquire Pacira BioSciences, Inc. - PRNewsWire
- 5 weeks ago - Pacira price target raised to $36.50 from $25 at RBC Capital - TheFly
- 5 weeks ago - Pacira downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 5 weeks ago - Pacira downgraded to Hold from Buy at Truist - TheFly